soul trial oral semaglutide cardiovascular outcomes 2024 nejm 2025 🔴 Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the soul trial oral semaglutide cardiovascular – VisualAbstract: Semaglutide Improves Outcomes in

Oral carnitine supplements are not invasive and are easy to add to daily routines

The FDA has reported adverse events, including hospitalizations, linked to overdoses and dosing errors with compounded semaglutide, often from patients measuring incorrectly or clinicians miscalculating

The agency also emphasised that the medication alone would not reverse the trend in obesity, which it recognised as a complex, chronic disease and a major driver of non-communicable diseases, including cardiovascular disease, type-2 diabetes and some types of cancer

Lim SW, Jin L, Jin J, Yang CW

Tirzepatide is one of the most-searched names in the GLP-1 landscape as of April 2026, and here we focus on what actually happens in the body during weight management

Obesity kills people through heart disease, diabetes, and multiple other pathways every single day